Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/nab-paclitaxel

被引：3
|
作者：
Park, Joon Oh
Kim, Seung Tae
Hong, Jung Yong
Kim, Seong-Jin
Park, Young Suk
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] GILO Fdn, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS632
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase 1b study of vactosertib in combination with oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine/nab-paclitaxel.
    Kim, Seung Tae
    Hong, Jung Yong
    Park, Young Suk
    Kim, Seong-Jin
    Park, Joon Oh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16299 - E16299
  • [2] Phase 1b Study of 2nd line vactosertib plus oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed firstline gemcitabine with nab-paclitaxel.
    Park, Joon Oh
    Kim, Seung Tae
    Hong, Eunji
    Hong, Jung Yong
    Park, Young Suk
    Kim, Seong-Jin
    CANCER RESEARCH, 2022, 82 (22) : 9 - 10
  • [3] Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM)
    Hammel, Pascal
    Bachet, Jean Baptiste
    Desrame, Jerome
    Meurisse, Aurelia
    Chibaudel, Benoist
    Debourdeau, Philippe
    Dauba, Jerome
    Lecomte, Thierry
    Seitz, Jean -Francois
    Tournigand, Christophe
    Aparicio, Thomas
    Guerin-Meyer, Veronique
    Taieb, Julien
    Volet, Julien
    Monier, Amandine
    Vernerey, Dewi
    Bonnetain, Franck
    Louvet, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).
    Dubreuil, Olivier
    Bachet, Jean Baptiste
    Hammel, Pascal
    Desrame, Jerome
    Meurisse, Aurelia
    Andre, Thierry
    Debourdeau, Philippe
    Dauba, Jerome
    Lecomte, Thierry
    Seitz, Jean Francois
    Tournigand, Christophe
    Aparicio, Thomas
    Meyer, Veronique Guerin
    Taieb, Julien
    Hiret, Sandrine
    Volet, Julien
    Monier, Amandine
    Chibaudel, Benoist
    Bonnetain, Franck
    Louvet, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [5] Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study
    Andrew, Dean
    Ramesh, Ramanathan
    Brooke, Belota
    Bruce, Belanger
    Deyaa, Adib
    Eliel, Bayever
    Chen Li-Tzong
    ANNALS OF ONCOLOGY, 2016, 27 : 84 - 84
  • [6] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [7] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [8] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [9] Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205).
    Lim, Kian-Huat
    Spencer, Kristen Renee
    Safyan, Rachael A.
    Picozzi, Vincent J.
    Varghese, Anna M.
    Siolas, Despina
    Perez, Kimberly
    Clift, Sheena
    Denis, Louis J.
    Bhambhani, Vijeta
    Hill, Stacey
    Pachter, Jonathan A.
    Pultar, Philippe
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM)
    Bachet, J. B.
    Hammel, P.
    Desrame, J.
    Chibaudel, B.
    Debourdeau, P.
    Dauba, J.
    Lecomte, T.
    Seitz, J. F.
    Tournigand, C.
    Aparicio, T.
    Meyer, V. Guerin
    Taieb, J.
    Volet, J.
    Bonnetain, F.
    Louvet, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S453 - S454
12345